Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick..
TheStreet Senior Columnist Adam Feuerstein discussed Bristol-Myers Squibb Co BMY on the show.
Feuerstein pointed out that the company announced Friday that it stopped a lung cancer drug trial early.
The news was positive because, according to Feuerstein, the drug was working so well and had “overwhelming efficacy.”
“That’s just more good news for Bristol-Myers,” Feuerstein said, as it would fuel further investor interest in cancer immunotherapy stocks.
Bristol-Myers recently traded at $65.49, up 2.84 percent.
Check out the full interview below. Feuerstein comes in at about the 1-hour mark:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.